Upstream Bio (UPB) Equity Average (2023 - 2026)

Upstream Bio's Equity Average history runs 4 years deep, the most recent figure standing at $321.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 29.68% year-over-year to $321.9 million; the TTM figure through Mar 2026 stood at $321.9 million (down 29.68% YoY), while the FY2025 annual figure was $404.8 million, up 133.51% from the prior year.
• Equity Average was $321.9 million for Q1 2026 at Upstream Bio, down from $359.2 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $457.7 million in Q1 2025 to a low of -$153.5 million in Q3 2024.
• Historically, Equity Average has averaged $157.5 million across 4 years, with a median of $238.3 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Equity Average soared 456.86% in 2025, then fell 29.68% in 2026.
• A 4-year view of Equity Average shows it stood at -$117.7 million in 2023, then jumped by 231.53% to $154.8 million in 2024, then jumped by 132.07% to $359.2 million in 2025, then retreated by 10.38% to $321.9 million in 2026.
• The last three Equity Average figures came in at $321.9 million (Q1 2026), $359.2 million (Q4 2025), and $393.7 million (Q3 2025), per Business Quant data.